A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Summary

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

Timeline

Start

2021-03-19

Primary completion

2023-02-10

Completion

2023-02-10

Publications

• Cong M, Carvalho Gontijo Weber R, Sakane S, Zhang V, Jiang C, Taura K, Kodama Y, DeMinicis S, Ganguly S, Brafman D, Chien S, Kramer M, Lupher M, Brenner DA, Xu J, Kisseleva T. Serum amyloid P (PTX2) attenuates hepatic fibrosis in mice by inhibiting the activation of fibrocytes and HSCs. Hepatol Commun. 2024 Oct 17;8(11):e0557. doi: 10.1097/HC9.0000000000000557. eCollection 2024 Nov 1.
• Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, Jenkins RG, Nathan SD, Raghu G, Walsh SLF, Jayia PK, Kamath N, Martinez FJ. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial. Am J Respir Crit Care Med. 2024 May 1;209(9):1132-1140. doi: 10.1164/rccm.202401-0116OC.
• Mantovani A, Garlanda C. Humoral Innate Immunity and Acute-Phase Proteins. N Engl J Med. 2023 Feb 2;388(5):439-452. doi: 10.1056/NEJMra2206346. No abstract available.

Drugs

Indications